Discovery and Optimization of Selective Inhibitors of Large Tumor Suppressor Kinases LATS1 and 2 for In Vivo Investigation of the Hippo-YAP Pathway in Tissue Regeneration

Large Tumor Suppressor kinases LATS1 and 2 (LATS1/2) are serine/threonine kinases and core regulators of the Hippo-YAP pathway. Inhibition of LATS1/2 promotes nuclear translocation of nonphosphorylated YAP, thereby initiating a downstream cascade promoting cell proliferation. We set out to investigate the potential of LATS inhibition as a therapeutic approach to enhance tissue regeneration and hereby report a structure-guided optimization of screening hit <b>1</b> for potency, binding efficiency, and physicochemical properties, leading to a highly selective, cellularly active, and orally available tool compound <b>7</b> (NIBR-LTSi) that demonstrated <i>ex vivo</i> target engagement and in vivo YAP target gene activation in rodents.

Authors

Institutions

Publication Details

Journal
Journal of Medicinal Chemistry
Published
2025-06-27
DOI
https://doi.org/10.1021/acs.jmedchem.5c00350
Citations
1
Primary Topic
Hippo pathway signaling and YAP/TAZ
Type
article
Field-Weighted Citation Impact
1.15
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Discovery and Optimization of Selective Inhibitors of Large Tumor Suppressor Kinases LATS1 and 2 for In Vivo Investigation of the Hippo-YAP Pathway in Tissue Regeneration

Elizabeth George, Rainer Machauer, Clemens Scheufler, Felix Lohmann et al.
1 citations
Journal of Medicinal Chemistry
Hippo pathway signaling and YAP/TAZ
1.15
article

Discovery and Optimization of Selective Inhibitors of Large Tumor Suppressor Kinases LATS1 and 2 for In Vivo Investigation of the Hippo-YAP Pathway in Tissue Regeneration

Elizabeth George, Rainer Machauer, Clemens Scheufler, Felix Lohmann, Louis Wang, Bindi Sohal, Ralf Glatthar, Mickaël Sorge, F.P.A. Fabbiani, Jan S. Tchorz, Kerstin Barker, Lauren E. Connor, Eric Vangrevelinghe, Andreas W. Sailer, Vincent Unterreiner, Julie Lachal, Kenji Namoto, Kathrin Schipp, Stéphane Laurent, Nicole Buschmann, Philippe Piéchon, Jürgen Maibaum, Emily Redmond, Dirk Behnke
article en
1 citations

Abstract

Large Tumor Suppressor kinases LATS1 and 2 (LATS1/2) are serine/threonine kinases and core regulators of the Hippo-YAP pathway. Inhibition of LATS1/2 promotes nuclear translocation of nonphosphorylated YAP, thereby initiating a downstream cascade promoting cell proliferation. We set out to investigate the potential of LATS inhibition as a therapeutic approach to enhance tissue regeneration and hereby report a structure-guided optimization of screening hit <b>1</b> for potency, binding efficiency, and physicochemical properties, leading to a highly selective, cellularly active, and orally available tool compound <b>7</b> (NIBR-LTSi) that demonstrated <i>ex vivo</i> target engagement and in vivo YAP target gene activation in rodents.

Journal of Medicinal ChemistryVol. 68(13)
Novartis (China) (CN)
Openalex Percentile: Top 23%
Hippo pathway signaling and YAP/TAZ
1.15
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.